Skip to main content
  • Research Letter
  • Open access
  • Published:

Effects of intermittent hemodialysis on plasmatic levels of endocan

To the editor,

Endocan is a prognostic biomarker of pulmonary and systemic inflammatory states [1], such as acute respiratory distress syndrome or sepsis, with substantial proportion of subjects requiring RRT [2]. In previous correspondences, Honoré et al. raised the question of the actual impact of hemodialysis on plasmatic levels of endocan in critically ill subjects [3, 4].

To address this question, we retrospectively collected serial measurements of endocan performed for routine care in EDTA plasma from 11 patients undergoing intermittent hemodialysis in a 50-bed ICU in Lille, France. Hemodialysis was performed using either ELISIO (Nipro, France), a polyethersulfone membrane with very low adsorptive capacities or EVODIAL (Baxter, USA), a heparin-grafted AN 69 ST membrane with higher adsorptive properties. Patients’ characteristics on ICU admission and on day of hemodialysis were collected retrospectively.

We categorized measurements of plasma endocan according to timing of blood collection relatively to hemodialysis, as following: T0, within 1 h before start of hemodialysis; T1, 30 min to 60 min after start of hemodialysis; T2, 90 min to 120 min after start of hemodialysis, T3, 180 min to 240 min after start of hemodialysis; T4: 90 min to 120 min after end of hemodialysis.

We are reporting characteristics of patients and of hemodialysis in Table 1 and kinetics of plasma endocan during hemodialysis in Fig. 1. We find a significant variation of endocan during the time course of hemodialysis, with median [IQR] values measured at 10.9 [4.3; 14.9] ng/ml at T0, 15.4 [5; 19.4] ng/ml at T1, 14.9 [5.4; 18.8] ng/ml at T2, 12.4 [6.1; 20] ng/ml at T3, 10.1 [4.2; 16.1] ng/ml at T4 (p = 0.025). In addition, relatively to values observed at T0, we found significant increases of median [IQR] plasma endocan variations at T1 (+ 22% [+ 12%; + 72%], p = 0.006), T2 (+ 34% [-4%; + 68%], p = 0.019), and T3 (+ 27% [+ 5%; + 56%], p = 0.014), but not at T4 (+ 34% [-8%; + 57%], p = 0.053). Noteworthy, our analyses suggest that the variations of endocan depend on the type of membrane, with lower increases in the EVODIAL group (p = 0.009 by linear mixed model). This lower increase in endocan blood levels seems consistent with greater adsorption properties of EVODIAL membranes. However, because of the limited number of patients in the EVODIAL group, this result should be interpreted with caution.

Table 1 Characteristics of patients
Fig. 1
figure 1

a Box plots of plasma endocan values during hemodialysis. Box plots show median, 1st and 3rd quartiles, and whiskers at 1.5-time interquartile range. Comparisons between paired values were performed using Friedman test. b Variations of plasma endocan relatively to values measured at T0. Comparisons between values at each time point with T0 value were performed using Wilcoxon-signed ranks test. c Values of endocan expressed in ng/ml at each time point. Patients are shown in yellow rows in case of hemodialysis with EVODIAL membranes and blue rows in case of ELISIO membranes. We used a linear mixed model with type of membrane set as fix effect and timing of blood collection set as random effect to assess the effect of the type of membrane on variations of endocan during hemodialysis. Plasma endocan was measured at the Immunology Institute of Lille Teaching Hospital, France, using the ENDOMARK H1 ELISA kit (Biothelis, France). T0: sampling within 1 h before start of hemodialysis. T1: sampling 30–60 min after start of hemodialysis. T2: sampling 90–120 min after start of hemodialysis. T3: sampling 180–240 min after start of hemodialysis. T4: sampling 90–120 min after end of hemodialysis. All statistical tests were two-tailed, and p values < 0.05 were considered statistically significant. All data analyses were performed using R, version 3.6 (R Foundation for Statistical Computing, Austria). *p < 0.05. **p < 0.01. ns: non-significant

Our results suggest an increase in levels of plasma endocan at the initial phase of hemodialysis. This may be explained by the response to vascular stress, resulting in an increase in secretion of endocan [1], or by hemoconcentration, which may occur during hemodialysis. Interestingly, the quick raise in endocan blood levels is consistent with previous data from a human LPS-induced endothelial stress model [5]. Additionally, our data tend to show a progressive decrease of plasma endocan during the time course of hemodialysis, possibly related to alleviation of endothelial stress or actual elimination of endocan. Adsorption on the membrane may explain this progressive decrease in blood levels of endocan, as suggested by the likely influence of adsorptive properties of the membranes on the variations of endocan. Conversely, the possibility that this decrease could be explained by diffusion mechanisms seems unlikely, given the 50 kDa molecular weight of endocan, exceeding the diffusion properties expected with our hemodialysis settings [6]. Similar mechanisms should be observed during continuous renal replacement therapy (CRRT), potentially resulting in greater removal of plasma endocan, because of longer RRT durations in CRRT.

Hence, these results suggest major interference of hemodialysis with blood concentrations of endocan, especially when highly adsorptive membranes are used, making it unreliable as a prognostic biomarker of pulmonary and systemic inflammation in critically ill patients undergoing hemodialysis.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.


  1. De Freitas CN, Gaudet A, Portier L, Tsicopoulos A, Mathieu D, Lassalle P. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care Lond Engl. 2018;22:280.

    Article  Google Scholar 

  2. Peters E, Antonelli M, Wittebole X, Nanchal R, François B, Sakr Y, et al. A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from The Intensive Care Over Nations audit. Crit Care Lond Engl. 2018;22:188.

    Article  Google Scholar 

  3. Honore PM, De Bels D, Attou R, Redant S, Gallerani A, Kashani K. Endocan removal during continuous renal replacement therapy: does it affect the reliability of this biomarker? Crit Care Lond Engl. 2019;23:184.

    Article  Google Scholar 

  4. Honore PM, Redant S, De Bels D. Reliability of biomarkers of sepsis during extracorporeal therapies: the clinician needs to know what is eliminated and what is not. Crit Care Lond Engl. 2020;24:553.

    Article  Google Scholar 

  5. Cox LAE, van Eijk LT, Ramakers BPC, Dorresteijn MJ, Gerretsen J, Kox M, et al. Inflammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock Augusta Ga. 2015;43:322–6.

    Article  CAS  Google Scholar 

  6. Pino CJ, Humes HD. Chapter 83—Renal replacement devices. In: Orlando G, Remuzzi G, Williams DF, editors. Kidney Transplant Bioeng Regen. Academic Press; 2017 [cited 2021 Nov 6]. p. 1135–49.

Download references


Not applicable.



Author information

Authors and Affiliations



MH, JP, DM, and AG designed the whole study, conducted data analyses, and drafted the manuscript. SD performed the biological measurements. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Alexandre Gaudet.

Ethics declarations

Ethics approval and consent to participate:

In accordance with the French law, and because of the retrospective observational design, written informed consent was not required for this study. Data collection for this study was declared to and approved by the Commission Nationale de l'Informatique et des Libertés (CNIL/Declaration Number DEC19-450). Accordingly, patients included in this study received an information letter, as required by the French law.

Consent for publication

Not applicable.

Competing interests

The authors have disclosed that they do not have any conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hureau, M., Poissy, J., Mathieu, D. et al. Effects of intermittent hemodialysis on plasmatic levels of endocan. Crit Care 25, 412 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: